KAYE
17.12.2020 10:02:15 CET | Business Wire | Press release
Kaye has been a leader for over 60 years in the Validation and Monitoring of critical process data. With its introduction of the Kaye Log -80 Vaccine Temperature Logger and KayeTrack Cloud Kaye has applied the same quality principles to ensure the validation and safety of the Cold Chain. This NFC Logger with external probe allows the precise recording and monitoring of products that are using Dry Ice pellets for Cold Chain shipment and storage. Shipments of vaccines and plasma at -70°C (-94°F) are very sensitive for breaking of the container seal, which will quickly allow the internal temperatures to rise to a critical level.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201217005380/en/
Drugs, vaccines, blood and biological materials are extremely sensitive to temperature variations. They must be kept and transported within a controlled temperature range during storage and transit; these are well known facts. However, during the recent fight against the COVID-19 Pandemic and with vaccines on the horizon, the demand for 24/7 temperature monitoring within the Cold Chain received another requirement, ultra-low measurements down to -70C. Besides the technology of monitoring at ultra-cold temperatures, the requirement of fast access to the temperature data without disturbing the integrity of the packaging, is foremost. Any removal of the logging device from the package, use of USB and local software applications will impede the process flow. Threshold LEDS allow the recipient to quickly see if the threshold limits have been breached, and with a quick swipe of an NFC device, all data is loaded to a local smart phone application and to the KayeTrack cloud, with corresponding email alerts, emailed PDF reports and GPS location information.
The Kaye Log -80 Vaccine Temperature Logger is an extension of Kaye’s Cold Chain solutions. From Thermal Validation, Continuous Monitoring, and Cold Chain Loggers, Kaye is committed to providing accurate, reliable, secure data and systems to help ensure the quality of all Pharma/Biotech products.
For information on the product, please visit https://www.kayeinstruments.com/kaye-log-80-vaccine-temperature-logger
About Kaye
For more than sixty years, Kaye has been at the forefront of high accuracy process measurement, for applications from thermal process validation and environmental and cold chain monitoring, to sensor calibration. https://www.kayeinstruments.com
Kaye is a subsidiary of Amphenol Corporation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005380/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Money20/20 Europe Announces Powerhouse Speaker Lineup Featuring Leaders from Klarna, BBVA, ABN AMRO, Mastercard, eToro, and Revolut19.5.2026 10:10:00 CEST | Press release
Leading voices in payments, banking, and fintech innovation to take the stage in Amsterdam Money20/20, the world’s leading fintech show and the place where money does business, today announced a stellar line-up of speakers for Money20/20 Europe happening on June 2-4 at the RAI in Amsterdam. The show will feature 450+ speakers across six stages, exploring the forces redefining global finance through AI innovation, digital assets, and regulatory transformation. Newly confirmed speakers include some of the most influential voices shaping the future of payments, banking, and financial services: Sebastian Siemiatkowski, Co-Founder and CEO, Klarna. A pioneer in the buy now, pay later revolution, Siemiatkowski has transformed consumer payments and continues to drive innovation in embedded finance and AI-powered shopping experiences. Onur Genç, CEO, BBVA. Leading one of Europe's most digitally advanced banks, Genç is at the forefront of banking transformation, leveraging data, technology, and
Mythic Acquires Videantis, One of Europe’s Leading Digital Processor IP Companies, to Build the World’s Most Energy-Efficient AI Compute Platform19.5.2026 10:00:00 CEST | Press release
Silicon Valley and German engineering unite to create a new AI compute champion for Europe and the world Mythic, a pioneer in analog compute-in-memory and architect of the industry’s most energy-efficient AI acceleration technology, today announced it has acquired Videantis GmbH, one of Europe’s leading digital processor IP companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519255958/en/ The transaction unites Mythic’s breakthrough analog compute platform with Videantis’ highly differentiated, unified digital processor architecture and production-proven software stack — accelerating Mythic’s delivery of a new class of hybrid AI compute platform with a 100x energy efficiency advantage over conventional GPU-based systems. This deal builds on Mythic’s recently announced agreement with Honda to co-develop next-generation AI chips for future vehicles — a validation of Mythic’s game-changing architecture in one of the wo
Splio Enters a New Phase of Its Regional Development in Southern Europe19.5.2026 09:00:00 CEST | Press release
As consumers integrate AI into their everyday web usage, Splio is strengthening its presence in Barcelona to help companies across the region make CRM a central lever in the age of agentic commerce Splio is strengthening its presence in Barcelona, which is set to play the role of a second headquarters, to drive its development across Southern Europe.Splio is reinforcing governance, teams and resources deployed in the region.With its AI-first CRM, Splio aims to help companies from retail to travel strengthen the business contribution of CRM. A few months after launching its AI-first CRM, Splio is entering a new phase of its development in Southern Europe. Already established for more than 12 years in Spain, Portugal and Italy, the company has chosen to invest further in the region, convinced that it combines economic potential with rapidly evolving digital usage. Antoine Parizot, Splio’s co-CEO, is relocating to Barcelona, where the company’s historic office is based. At the same time,
KfW, Germany’s largest national promotional bank, future-proofs regulatory reporting, by migrating to Regnology Reporting Hub (RRH)19.5.2026 08:33:00 CEST | Press release
Longstanding client transitions to the next-generation RRH solution, delivered on Regnology’s Rcloud architecture Regnology, a leading provider at the intersection of regulatory, risk, and supervisory technology, today announced that KfW Bankengruppe (KfW) is advancing its long-term partnership with the company by electing to migrate to the next-generation Regulatory Reporting Hub (RRH). The solution will be delivered as a cloud-native service on Rcloud, Regnology’s high-performance cloud architecture layer. This strategic move to the modern RRH platform future-proofs the mission-critical reporting functions for one of the world's leading promotional banks. Headquartered in Frankfurt am Main, KfW is a public‑law institution dedicated to supporting sustainable economic, social and ecological development in Germany, across Europe and globally. Regnology’s foresight led to the 2023 launch of Rcloud, its state-of-the-art architecture layer built on Google Cloud, enabling next‑generation so
ATB Therapeutics Appoints Mark Throsby as CEO to Lead Next Phase of Growth19.5.2026 08:00:00 CEST | Press release
ATB Therapeutics (“ATB” or the “Company”), a biopharmaceutical company advancing next-generation antibody-based therapies for oncology and immunology, today announced the appointment of Mark Throsby, PhD, as Chief Executive Officer. The leadership transition marks an important milestone as the Company continues its evolution from a startup into a development-stage biopharmaceutical company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513198633/en/ ATB Therapeutics Appoints Mark Throsby as CEO to Lead Next Phase of Growth Mark Throsby has served as Executive Chairman and Chief Scientific Officer since 2024, during which time he supported the Company’s growth, including the successful closing of its Series A financing, the expansion of the scientific team, and the advancement of its therapeutic programs. In his new role, he will lead ATB’s strategy and senior leadership team as the Company prepares to enter clinical deve
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom